Brian Schmitt - Auxly Cannabis Chief Officer
| XLY Stock | CAD 0.08 0.01 5.88% |
Insider
Brian Schmitt is Chief Officer of Auxly Cannabis Group
| Address | 777 Richmond Street West, Toronto, ON, Canada, M6J 0C2 |
| Phone | (647) 812-0121 |
| Web | https://www.auxly.com |
Brian Schmitt Latest Insider Activity
Tracking and analyzing the buying and selling activities of Brian Schmitt against Auxly Cannabis stock is an integral part of due diligence when investing in Auxly Cannabis. Brian Schmitt insider activity provides valuable insight into whether Auxly Cannabis is net buyers or sellers over its current business cycle. Note, Auxly Cannabis insiders must abide by specific rules, including filing SEC forms every time they buy or sell Auxly Cannabis'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Brian Schmitt over a year ago Acquisition by Brian Schmitt of 1500 shares of Colony Bankcorp subject to Rule 16b-3 | ||
Brian Schmitt over a year ago Payment of 951 shares by Brian Schmitt of Colony Bankcorp subject to Rule 16b-3 |
Auxly Cannabis Management Efficiency
As of the 21st of March 2025, Return On Tangible Assets is likely to grow to -0.21. In addition to that, Return On Capital Employed is likely to grow to -0.13. At this time, Auxly Cannabis' Total Assets are very stable compared to the past year. As of the 21st of March 2025, Non Current Assets Total is likely to grow to about 236.6 M, while Other Current Assets are likely to drop about 3 M. Auxly Cannabis' management efficiency ratios could be used to measure how well Auxly Cannabis manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Matthew Rogers | OrganiGram Holdings | N/A | |
| Chris Halyk | Medipharm Labs Corp | N/A | |
| Geoff Riggs | OrganiGram Holdings | N/A | |
| Cameron Bishop | OrganiGram Holdings | N/A | |
| Miriam McDonald | Medipharm Labs Corp | N/A | |
| Timothy Emberg | OrganiGram Holdings | N/A | |
| Chris Taves | Medipharm Labs Corp | N/A | |
| Dara Redler | Tilray Inc | N/A | |
| Raymond Gracewood | OrganiGram Holdings | N/A | |
| Lloyd Brathwaite | Tilray Inc | N/A | |
| CPA CPA | OrganiGram Holdings | 55 | |
| Keith Strachan | Medipharm Labs Corp | N/A | |
| Denise Faltischek | Tilray Inc | 52 | |
| Sybil Taylor | Medipharm Labs Corp | N/A | |
| Warren Everitt | Medipharm Labs Corp | N/A | |
| CFA CA | OrganiGram Holdings | 52 | |
| Shelley Martin | Medipharm Labs Corp | N/A | |
| Tina Shannon | OrganiGram Holdings | N/A | |
| Beena Goldenberg | OrganiGram Holdings | 62 | |
| Paul Tam | Medipharm Labs Corp | N/A | |
| Nigel Dewsbury | Medipharm Labs Corp | N/A | |
Management Performance
| Return On Equity | -0.71 | ||||
| Return On Asset | -3.0E-4 |
Auxly Cannabis Group Leadership Team
Elected by the shareholders, the Auxly Cannabis' board of directors comprises two types of representatives: Auxly Cannabis inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Auxly. The board's role is to monitor Auxly Cannabis' management team and ensure that shareholders' interests are well served. Auxly Cannabis' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Auxly Cannabis' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ian Rapsey, Chief Officer | ||
| Ron Fichter, General Secretary | ||
| Hugo Alves, CEO Director | ||
| Vladimir Klacar, Senior Planning | ||
| Alan Cooke, VP Operations | ||
| Brian Schmitt, Chief Officer | ||
| Kevin Furet, Chief Officer | ||
| Michael Lickver, President | ||
| Andrew MacMillan, Senior Commercial | ||
| Carla Nawrocki, Senior Strategy | ||
| Travis Wong, Chief Officer |
Auxly Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Auxly Cannabis a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.71 | ||||
| Return On Asset | -3.0E-4 | ||||
| Profit Margin | (0.65) % | ||||
| Operating Margin | 0.19 % | ||||
| Current Valuation | 159.06 M | ||||
| Shares Outstanding | 1.25 B | ||||
| Shares Owned By Insiders | 21.23 % | ||||
| Shares Owned By Institutions | 0.16 % | ||||
| Number Of Shares Shorted | 736.52 K | ||||
| Price To Book | 0.96 X |
Other Information on Investing in Auxly Stock
Auxly Cannabis financial ratios help investors to determine whether Auxly Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Auxly with respect to the benefits of owning Auxly Cannabis security.